SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003271 to Pluri Inc. (PLUR)

Pluri Inc.
Date: March 26, 2025 · CIK: 0001158780 · Accession: 0000000000-25-003271

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 001-31392

Date
March 26, 2025
Author
Finance
Form
UPLOAD
Company
Pluri Inc.

Letter

Re: Pluri Inc. Preliminary Proxy Statement on Schedule 14A Filed March 14, 2025 File No. 001-31392 Dear Liat Zalts:

March 26, 2025

Liat Zalts Chief Financial Officer Pluri Inc. Matam Advanced Technology Park Building No.5 Haifa, Israel, 3508409

We have reviewed your filing and have the following comment.

Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this letter, we may have additional comments.

Preliminary Proxy Statement on Schedule 14A Proposal No. 6 - Private Placement Proposal, page 14

1. We note that Proposal No. 6 seeks shareholders of Pluri Inc. to approve the exercise of the Warrants and the issuance of the Consideration Shares in connection with the acquisition of a majority of the equity interests in Kokomodo Ltd. Insofar as your shareholders will not have a separate opportunity to vote on that transaction, please revise your disclosure to include the information required pursuant to Note A of Schedule 14A, including the information set forth in Items 11, 13, and 14 of Schedule 14A. Refer to Question and Answer 151.02 of the Compliance and Disclosure Interpretations for Proxy Rules and Schedules 14A/14C available on our website. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. March 26, 2025 Page 2

Please contact Doris Stacey Gama at 202-551-3188 or Tim Buchmiller at 202-551- 3635 with any other questions.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Ron Ben-Bassat, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 26, 2025

Liat Zalts
Chief Financial Officer
Pluri Inc.
Matam Advanced Technology Park
Building No.5
Haifa, Israel, 3508409

 Re: Pluri Inc.
 Preliminary Proxy Statement on Schedule 14A
 Filed March 14, 2025
 File No. 001-31392
Dear Liat Zalts:

 We have reviewed your filing and have the following comment.

 Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

 After reviewing your response to this letter, we may have additional
comments.

Preliminary Proxy Statement on Schedule 14A
Proposal No. 6 - Private Placement Proposal, page 14

1. We note that Proposal No. 6 seeks shareholders of Pluri Inc. to approve
the exercise
 of the Warrants and the issuance of the Consideration Shares in
connection with the
 acquisition of a majority of the equity interests in Kokomodo Ltd.
Insofar as your
 shareholders will not have a separate opportunity to vote on that
transaction, please
 revise your disclosure to include the information required pursuant to
Note A of
 Schedule 14A, including the information set forth in Items 11, 13, and
14 of Schedule
 14A. Refer to Question and Answer 151.02 of the Compliance and
Disclosure
 Interpretations for Proxy Rules and Schedules 14A/14C available on our
website.
 We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.
 March 26, 2025
Page 2

 Please contact Doris Stacey Gama at 202-551-3188 or Tim Buchmiller at
202-551-
3635 with any other questions.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
cc: Ron Ben-Bassat, Esq.
</TEXT>
</DOCUMENT>